Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

2022239 citationsJournal Articlehybrid Open Access

Authors

Thierry André · Hôpital Saint-Antoine

Sara Lonardi · Istituti di Ricovero e Cura a Carattere Scientifico

Ka Yeung Mark Wong · Westmead Hospital

H.J. Lenz · University of Southern California

Fabio Gelsomino

Massimo Aglietta · Candiolo Cancer Institute

Michael A. Morse · Duke Medical Center

Abstract

The results confirm long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC. The safety profile was manageable with no new safety signals.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Genetic factors in colorectal cancer Colorectal Cancer Treatments and Studies

Publication Details

Published in: Annals of Oncology

Volume 33, Issue 10, pp. 1052-1060

DOI: 10.1016/j.annonc.2022.06.008

Field-Weighted Citation Impact: 23.67

Command Palette

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Authors

Abstract

Topics & Keywords

Publication Details